Kim's Breast Cancer Case Study Video

From surgery to surveillance: Managing referrals for germline and ctNDA testing

Amanda Invasive Ductal Carcinoma

Hear Amanda's journey with Signatera that helped her team catch relapse earlier.

NateraConnect Pathology

Kim Early Stage Breast Cancer Patient

How Kim's story and how Signatera served as an informative tool for post definitive treatment surveillance.

Beyond bladder cancer: A multidisciplinary approach to MRD testing in RCC

Rachelle's Story HR+ Breast Cancer

Stage IIB HR+/HER2- Breast Cancer (BRCA2 mutation+)

Natera Oncology Biopharma

Navigating Low-Level ctDNA Positive: Interpretation, Context and Actionability

Navigating MIBC management: Integrating ctDNA into clinical practice

NateraConnect Single and Combo Orders

A clinical perspective from Dr. Siddharth Sheth

See how Signatera™ MRD testing flagged HNSCC recurrence before CT imaging, providing a lead-time advantage that can inform treatment.

Redefining HNSCC Management with Signatera™ MRD Testing: A Multidisciplinary Perspective

My patient is Signatera-positive. Now What?

MRD Insights for Radiation Oncology in NSCLC

ASBrS 2026: Optimizing Breast Cancer

Leading Breast Surgeons Discuss MRD Testing

Introducing Signatera, a personalized, tumor-informed test

Driving clinical development with real-world molecular intelligence

Signatera Test